AstraZeneca and Merck seek to add a pancreatic cancer indication for olaparib, while Merck has hopes of broadening pembrolizumab’s use in bladder cancer; two-day Oncologic Drugs Advisory Committee meeting also will include reviews of Celgene’s luspatercept in myelodysplastic syndromes-related anemia and Epizyme’s tazemetostat for epithelioid sarcoma.
The US Food and Drug Administration will close out 2019 with a two-day Oncologic Drugs Advisory Committee meeting encompassing four applications – two for supplemental indications and two original submissions – in mid-December.
On the morning of 17 December, ODAC will discuss the addition of a pancreatic cancer indication for AstraZeneca PLC...